Drug Trial Radar · NCT02283177
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
Last checked: Nov 19, 2026Latest source record: Feb 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Jan 2015
Primary completion
Dec 2019
Study completion Dec 2019
Sponsor
- Lead sponsor
- Arog Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 5, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pilot study is designed to evaluate the safety and tolerability of oral crenolanib besylate given sequentially during standard induction and consolidation chemotherapy in patients with newly diagnosed AML with FLT3 activating mutations.
Conditions
- Newly Diagnosed AML With FLT3 Activating Mutations
Interventions
crenolanibDrug
cytarabineDrug
daunorubicinDrug
idarubicinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Response to Crenolanib With Standard Induction ChemotherapyTime frame: 2 years
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Medical Center
Duarte, California
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Dana-Farber Cancer Institute
Boston, Massachusetts
Roswell Park Cancer Institute
Buffalo, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Weill Cornell Medical College
New York, New York
Cleveland Clinic
Cleveland, Ohio
University of Texas Southwestern Medical Center
Dallas, Texas
Fred Hutchinson Cancer Research Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.